Patents Issued in November 20, 2018
  • Patent number: 10130657
    Abstract: A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxidation therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.
    Type: Grant
    Filed: February 14, 2016
    Date of Patent: November 20, 2018
    Inventor: John C. Hughes
  • Patent number: 10130658
    Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 20, 2018
    Assignees: Provectus Pharmatech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
  • Patent number: 10130659
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 20, 2018
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10130660
    Abstract: The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: November 20, 2018
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Young-Bae Park, Hyo-Soo Kim, Hyun-Jae Kang, Jin Hur, Jeehoon Kang, Jung-Kyu Han, Ji-Yeon Yun, Jae-Il Choi, Jin-A Kang
  • Patent number: 10130661
    Abstract: The present invention provides devices and methods for improving wound healing, in particular, in diabetic subjects.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 20, 2018
    Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc., Trustees of Tufts College
    Inventors: Aristidis Veves, David J. Mooney, Jonathan Garlick
  • Patent number: 10130662
    Abstract: A delivery system for delivery of a therapeutic agent such as stem cells into a vein and across a micro circulation system into an artery comprises a multi lumen catheter for delivery of a therapeutic agent. A discharge device is located in a vein. The operation of the delivery device is controlled by a pressure stem cell solution delivery gun system. There are multiple delivery stages. These may include delivery of an elixir to open up the pressure bed, a platelet-rich plasma, stem cells, scaffolds, and finally an elixir to provide emichment and nourishment of the stem cells.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 20, 2018
    Assignee: Tulip Endovascular Innovation Limited
    Inventors: Sherif Sultan, Niamh Hynes
  • Patent number: 10130663
    Abstract: The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: November 20, 2018
    Assignee: The John Hopkins University
    Inventors: William R. Bishai, Ruchi Jain Dey, Bappaditya Dey, Laurene Cheung
  • Patent number: 10130664
    Abstract: The present invention relates probiotic compositions useful in accelerating alcohol catabolism in a subject.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: November 20, 2018
    Assignee: BiOWiSH Technologies, Inc.
    Inventors: Richard Carpenter, Amit Kapur, E. Wesley Huff, Narayan Suresh
  • Patent number: 10130665
    Abstract: A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harboring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: November 20, 2018
    Assignee: GENOME RESEARCH LIMITED
    Inventors: Trevor D. Lawley, Simon Clare, Gordon Dougan
  • Patent number: 10130666
    Abstract: The present invention provides Lactobacillus plantarum CJLP133 KCTC 11403BP, a composition for treating intestinal diseases comprising the lactic acid bacteria, and a composition for enhancing immunity comprising the lactic acid bacteria.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 20, 2018
    Assignee: CJ CHEILJEDANG CORP
    Inventors: Bong Joon Kim, Heon Woong Jung, Se Hee Hwang, Jin Hee Lee, Kang-Pyo Lee, Kwang Woo Hwang, Tae Joon Won
  • Patent number: 10130667
    Abstract: The present invention relates to a vaccine comprising the insertion of three genes, the TAA/ecdCD40L EA1 and CDA, driven by promoters L-plastin/cytosinedeaminase and CMV as a three gene, three transcription unit oncolytic virus as a conditionally replication competent adenoviral vector which replicates only in tumor cells. In these transcription units, the E1A gene of the adenoviral vector as well as the cytosine deaminase gene are under the control of the L-plastin promoter, while the TAA/ecdCD40L transcription unit is under control of a the CMV promoter.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 20, 2018
    Assignee: MicroVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10130668
    Abstract: Provided is a use of Dendropanax morbifera extract as an agent for preventing and treating benign prostatic hyperplasia, and more particularly, a composition for preventing and treating benign prostatic hyperplasia and a functional health food for preventing and reducing the effects of benign prostatic hyperplasia, in which the composition and food include, as an active ingredient, a Dendropanax morbifera extract or a compound which is isolated from the extract and then purified.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: November 20, 2018
    Assignee: Industry-Academic Cooperation Foundation, Chosun University
    Inventors: Cheol-Hee Choi, Young-Sook Moon, Ju-Hee Han, Kyoung-In Lee, Hyun-Jung Kim
  • Patent number: 10130669
    Abstract: A method and a system comprise receiving an amount of a first disinfecting solution on and around a wound. An amount of a second disinfecting solution is received on and around the wound. An amount of a third disinfecting solution is received on and around the wound. An amount of a fourth disinfecting solution is received around the wound. Cold laser emissions are received on and around the wound. The cold laser emissions comprise at least multiple wavelengths. A sterile gauze bandage and wrap cover the wound.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: November 20, 2018
    Inventor: Ronald K. Gilbert
  • Patent number: 10130670
    Abstract: The present invention relates to a composition for treating or preventing an inflammatory skin disease, comprising, as an active ingredient, an unripe Citrus unshiu fruit extract and/or Synephrine or salt thereof. The composition of the present invention prevents an inflammatory reaction by inhibiting activity of STAT6, expression of eotaxin-1 and an agglomeration function of eosinophil, and thus, shows effects of preventing and treating an allergic inflammatory disease, atopic dermatitis, eczema, psoriasis, etc. Also, the composition of the present invention does not have cytotoxicity and a skin side effect, and thus, can be safely applied to pharmaceutical products and cosmetics.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 20, 2018
    Assignee: BIOSPECTRUM, INC.
    Inventors: Kyung Baeg Roh, Young Soo Kim, Eun Sun Jung, Deok Hoon Park
  • Patent number: 10130671
    Abstract: Embodiments described herein provide for uses of grape products, such as Chardonnay grape products and grape seed flour, for use in promoting a healthy liver, promoting healthy fat content in a liver, for treating or preventing NAFLD, and other embodiments and uses as described herein.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 20, 2018
    Assignees: SONOMACEUTICALS, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Torey James Arvik, Hyunsook Kim, Wallace H. Yokoyama, Scott R. Forsberg
  • Patent number: 10130672
    Abstract: The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: November 20, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: Ravigadevi Sambanthamurthi, Kalyana Sundram P. Manickam, Yew Ai Tan, Mohd Basri bin Wahid
  • Patent number: 10130673
    Abstract: A method of reducing TNF-? production in human epidermal keratinocytes, the method comprising topically applying to skin in need thereof a composition comprising an effective amount of a liquid kakadu plum extract comprising kakadu plum fruit, alcohol, and butylene glycol to reduce TNF-? production in human epidermal keratinocytes of the skin, and an effective amount of a liquid acai berry extract comprising acai berry fruit, water, and alcohol to reduce TNF-? production in human epidermal keratinocytes of the skin.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 20, 2018
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Michelle Hines, Javier Aravena, Brian Jones
  • Patent number: 10130674
    Abstract: Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT (SEQ ID NO:1) exhibits potent antagonism for both CCR2 (IC50 4.2 pM) and CCR5 (IC50 0.18 pM) in monocyte chemotaxis. Oral administration of All D TTNYT (SEQ ID NO:1) (0.05-1 mg/kg) for 7 days fully prevents mechanical allodynia and inhibits the development of thermal hyperalgesia following partial ligation of the sciatic nerve in rats. Administered from day 8 to day 12, All D TTNYT (SEQ ID NO:1) (0.2-1 mg/kg) reverses already established hypersensitivity.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 20, 2018
    Assignee: Creative Bio-Peptides
    Inventors: Candace Pert, Michael Ruff
  • Patent number: 10130675
    Abstract: The present invention aims to provide a wound healing agent that inhibits bacterial growth, promotes granulation tissue formation and epithelization, and minimizes foreign body reaction in the granulation tissue. The wound healing agent of the present invention contains protein (A) and water, wherein the protein (A) contains: GAGAGS (1); and an amino acid sequence (X) and/or an amino acid sequence (X?), and the total percentage of ? turns and random coils in the protein (A) as determined by circular dichroism spectroscopy is 60 to 85%, and the percentage of the total number of amino acid residues in the amino acid sequences (X) and (X?) is 50 to 70% of the total number of amino acid residues in the protein (A). Amino acid sequence (X): at least one amino acid sequence selected from the group consisting of VPGVG (2), GVGVP (3), and GAHGPAGPK (4).
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: November 20, 2018
    Assignee: SANYO CHEMICAL INDUSTRIES, LTD.
    Inventor: Shingo Kawabata
  • Patent number: 10130676
    Abstract: The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, or variants, mutants, derivatives, or fragments thereof.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: November 20, 2018
    Assignee: Prime Bio-Drug Development Limited
    Inventor: Chen-Lung Lin
  • Patent number: 10130677
    Abstract: The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: November 20, 2018
    Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Academisch Medisch Centrum
    Inventors: Petrus Hendricus Nibbering, Anna de Breij, Robert Alexander Cordfunke, Sebastianus Antonius Johannes Zaat, Jan Wouter Drijfhout
  • Patent number: 10130678
    Abstract: Systems and methods for preparing synthetic osteoinductive bone grafts are provided in which a porous ceramic granule, which may be incorporated within a biocompatible matrix material, is loaded with an osteoinductive agent. Loading of granules is facilitated in some cases by the use of low-pH buffers and pre-treatments.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: November 20, 2018
    Assignee: Bioventus, LLC.
    Inventors: Eric Vanderploeg, Howard Seeherman, Christopher G. Wilson, John Wozney, Christopher T. Brown, John A. Kambouris
  • Patent number: 10130679
    Abstract: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an SRPX.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 20, 2018
    Assignee: University of Massachusetts
    Inventors: Michael R. Green, Guangping Gao, Manas Kumar Santra, Sanchita Bhatnagar
  • Patent number: 10130680
    Abstract: The technology described herein is directed to methods and compositions directed to the treatment of cancer, e.g. using multifunctional receptor targeted cancer therapeutics.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: November 20, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventor: Khalid Shah
  • Patent number: 10130681
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: November 20, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George D. Yancopoulos
  • Patent number: 10130682
    Abstract: A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 20, 2018
    Assignees: Ramot at Tel-Aviv University Ltd., Mor Research Applications Ltd.
    Inventors: Ruth Shalgi, Dana Chuderland, Hadas Bar-Joseph, Keren Goldberg, Irit Ben-Aharon, Salomon M. Stemmer
  • Patent number: 10130683
    Abstract: A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: November 20, 2018
    Assignee: University of South Florida
    Inventors: Cesario Venturina Borlongan, Paul R. Sanberg
  • Patent number: 10130684
    Abstract: Provided are orally administrable thin film dosage forms adapted to adhere to a mucosal tissue of a patient, wherein said film comprises mixtures of polymers and insulin.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: November 20, 2018
    Assignee: PHARMEDICA LTD.
    Inventors: Yoram Rubin, Smadar Cohen, Eyal S. Ron
  • Patent number: 10130685
    Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
  • Patent number: 10130686
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 20, 2018
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 10130687
    Abstract: Methods for reducing the severity of an arthritic condition or repairing an osteochondral defect are carried out by administering to a subject compositions comprising a member of the matrilin family of proteins, e.g., a matrilin protein, fragment thereof, or nucleic acid encoding the protein or fragment.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: November 20, 2018
    Assignee: Rhode Island Hospital
    Inventors: Qian Chen, Chathuraka T. Jayasuriya
  • Patent number: 10130688
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: November 20, 2018
    Assignee: Applied Molecular Transport Inc.
    Inventors: Randall Mrsny, Tahir Mahmood
  • Patent number: 10130689
    Abstract: The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: November 20, 2018
    Assignee: DIFFUSION PHARMACEUTICALS LLC
    Inventor: John L. Gainer
  • Patent number: 10130690
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Patent number: 10130691
    Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.
    Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
  • Patent number: 10130692
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: November 20, 2018
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 10130693
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: November 20, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10130694
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 20, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
  • Patent number: 10130695
    Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: November 20, 2018
    Assignees: Vedanta Biosciences, Inc., RIKEN
    Inventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
  • Patent number: 10130696
    Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 20, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
  • Patent number: 10130697
    Abstract: The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: November 20, 2018
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Shinji Watanabe, Tokiko Watanabe, Yoshihiro Kawaoka
  • Patent number: 10130698
    Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 20, 2018
    Assignee: Intervet Inc.
    Inventors: Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
  • Patent number: 10130699
    Abstract: The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 20, 2018
    Assignee: Intervet Inc.
    Inventors: Antonius Arnoldus Christiaan Jacobs, Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
  • Patent number: 10130700
    Abstract: This disclosure provides compositions that include a mixture of viral like particles (VLPs), expressing different individual influenza hemagglutinin (HA) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza VLPs, a first VLP comprising a first HA polypeptide and a second VLP comprising a second influenza HA polypeptide, wherein the first and the second HA polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant. Methods of using the disclosed polymeric influenza VLP compositions to stimulate an immune response against influenza viruses, for example as a pre-pandemic or a seasonal vaccine, are provided.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 20, 2018
    Assignee: The United States of America, as represented by the Secretary, DHHS
    Inventor: Jeffery K. Taubenberger
  • Patent number: 10130701
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Patent number: 10130702
    Abstract: The present disclosurerelates to a vaccine composition, wherein the vaccine composition comprises an immune amount of fowl adenovirus Fiber-2 protein or an immune amount of a live vector recombined with gene of the fowl adenovirus Fiber-2 protein, and a pharmaceutically acceptable carrier. The vaccine composition can provide effective immune protection against different serotypes of adenoviruses and provide a protection rate of 100% at low levels of immunogenic components, showing good immunological efficacy.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: November 20, 2018
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Wenqiang Pang, Jinzhong Sun, Xuke Zhang
  • Patent number: 10130703
    Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 20, 2018
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventor: Konstantin G. Kousoulas
  • Patent number: 10130704
    Abstract: The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of Helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 20, 2018
    Assignee: ONDEK PTY LTD
    Inventors: Mohammed Benghezal, Barry Marshall, Alma Fulurija, Senta Walton
  • Patent number: 10130705
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 20, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
  • Patent number: 10130706
    Abstract: The present disclosure provides topical biophotonic materials and methods useful in phototherapy. In particular, the topical biophotonic materials of the present disclosure include a cohesive matrix, and at least chromophore which can absorb and emit light from within the topical biphotonic material, wherein the topical biophotonic material is elastic. The topical biophotonic materials and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various other skin disorders.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 20, 2018
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Nikolaos Loupis, Remigio Piergallini, Éric DesRosiers